We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Clover Biopharmaceuticals Gets $66 Million From CEPI for COVID-19 Vaccine Trial
Clover Biopharmaceuticals Gets $66 Million From CEPI for COVID-19 Vaccine Trial
Chinese drugmaker Clover Biopharmaceuticals has received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its candidate COVID-19 vaccine.